Table 1—

Glycemic efficacy end points

ParameternBaselineWeek 24Least-squares change from baseline
A1C (%)
    Placebo2248.03 ± 0.827.95 ± 1.10−0.02 (−0.15 to 0.10)
    Sitagliptin 100 mg q.d.4537.96 ± 0.817.26 ± 0.97−0.67 (−0.77 to −0.57)*
FPG (mmol/l)
    Placebo2269.6 ± 2.39.9 ± 2.80.5 (0.2 to 0.8)
    Sitagliptin 100 mg q.d.4549.4 ± 2.38.4 ± 2.2−0.9 (−1.2 to −0.7)*
Insulin (pmol/l)
    Placebo19772.0 ± 45.672.0 ± 40.8−1.2 (−10.2 to 8.4)
    Sitagliptin 100 mg q.d.41972.6 ± 58.281.6 ± 76.27.8 (0.6–15.0)
Proinsulin-to-insulin ratio
    Placebo1690.37 ± 0.200.37 ± 0.210.02 (−0.02 to 0.05)
    Sitagliptin 100 mg q.d.3970.36 ± 0.210.33 ± 0.21−0.03 (−0.05 to 0.00)
C-peptide (nmol/l)
    Placebo1860.83 ± 0.400.87 ± 0.400.03 (−0.03 to 0.01)
    Sitagliptin 100 mg q.d.3900.83 ± 0.430.93 ± 0.430.10 (0.03–0.13)
HOMA-β
    Placebo19645.1 ± 34.247.6 ± 37.53.5 (−4.9 to 11.8)
    Sitagliptin 100 mg q.d.41846.4 ± 38.965.2 ± 68.919.5 (12.9–26.2)*
QUICKI
    Placebo1960.314 ± 0.0310.312 ± 0.028    −0.002 (−0.007 to 0.003)
    Sitagliptin 100 mg q.d.4180.315 ± 0.0320.318 ± 0.0360.003 (−0.000 to 0.007)
  • Data are means ± SD or mean (95% CI). To convert glucose from millimoles per liter to milligrams per deciliter, divide by 0.05551.

  • *

    * P < 0.001 vs. placebo;

  • P < 0.050 vs. placebo;

  • P < 0.010 vs. placebo.